| Name | Title | Contact Details |
|---|
The company`s proprietary CTreg™ (cryopreservation for Tregs) system is the first in the industry to create an `off the shelf` approach to Treg cell therapy allowing for serial infusions. Through our patented TAI™ (Tregs Against Inflammation) and EAI™ (Exosomes Against Inflammation) platforms , Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson`s, Alzheimer`s, FTD and autoimmune diseases.
INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient`s immune system to treat cancer. INKmune, the company`s lead product, primes patient`s NK cells (natural killer cells) to kill cancer.
Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.
GTx, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.